Exciting News and Updates From a Panel of Myeloma Experts From ASH 2015

Exciting News and Updates From a Panel of Myeloma Experts From ASH 2015

P2Professional

3 years
387 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
As part of Patient Power coverage from the 2015 American Society of Hematology (ASH), myeloma experts Dr. Noopur Raje, Dr. John Burke and Dr. Faith Davies, along with myeloma patient advocate Jack Aiello, gathered to discuss the latest news and research in multiple myeloma. The experts reviewed the recent approval of three new treatments, data presented on the power of combination therapy, important suggestions regarding prognosis and testing, and plenty of encouraging news based on presentations from the meeting. Each guest shares specific advice to myeloma patients to help them get the best care possible. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Up Next Autoplay
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
0 Views
cancernewsupdate 9 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 32 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 36 minutes
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
1 Views
ash 13 hours
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 13 hours
Brentuximab Vedotin with Chemotherapy #ASH19
Brentuximab Vedotin with Chemotherapy #ASH19
Category: Chronic Myelogenous Leukemia
0 Views
ash 19 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
4 Views
ash 21 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 22 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours